Karin & Sten Mortstedt CDB Solutions AB is deeply saddened to announce the passing of its founder and Chairman, Sten Mörtstedt
feb 2, 2021 | Mr. Mörtstedt passed away in December 2020 at the age of 80.
When his late wife Karin was diagnosed with Corticobasal Degeneration (CBD) syndrome in 2012, having witnessed the devastating effects- and the lack of awareness and knowledge of the disease, Mr. Mörtstedt founded Karin & Sten Mörtstedt CBD Solutions to bring together top researchers from renowned medical institutions in Europe and the US to increase the knowledge and unlock the potential to find treatments and a cure, and to help and support those suffering from CBD. Over the years, the Sten and Karin Mortstedt Family & Charity Trust has generously funded and actively supported CBD’s research studies and patient information.
Sten Mörtstedt was well known as a remarkable and successful entrepreneur in the property investment business. He will also be remembered for his generosity as a philanthropist, making a difference in the lives of others.
COVID-19 and CBD (Corticobasal Degeneration)
maj 29, 2020 | In response to the global outbreak of Covid-19 (Coronavirus) we are sure people with CBD, their families and carers will be concerned. Therefore we offer the following information at this difficult time. Read more
August 26, 2019 11:22 AM Eastern Daylight Time
aug 26, 2019 | Enigma Biomedical Group and CBD Solutions Sign Memorandum of Understanding to License Novel Investigational Tau R4 Imaging Biomarker.TORONTO - Enigma Biomedical Group (EBG) today announced execution of an Option Agreement to license CBD Solutions’s (CBD’s) Tau R4 imaging (TR4) biomarker CBD2115 . This option is intended to lead to an exclusive license wherein EBG will be responsible for the global development and commercialization of CBD’s early stage investigational imaging agent technology, which is being evaluated for use in Positron Emission Tomography (PET) scans to assess neurodegeneration. TR4 assessment promises to provide an important new tool in advancing understanding of a range of neurodegenerative diseases such as Progressive Supranuclear Palsy, Corticobasal Degeneration and other dementias.
Press release: CBD Solutions will support PSP association UK to develop Pathway of Care for CBD
aug 30, 2018 | 30 Aug. CBD Solutions will support PSP association UK to develop Pathway of Care for CBD. More info will follow after The First International Symposium on PSP & CBD in London 25-26 of October. Read more
Press release – New CBD patient registry
dec 8, 2016 | European registry for CBD patient has been launched. Currently 44 European sites participates and If you are interested in participating or would like further information please contact Dr Ruth Lamb at UCL in London (email@example.com)
Press Release: CBD Solutions Investigator, John Hardy of UCL, recognised for his pioneering research in Alzheimer’s
nov 19, 2015 | CBD Solutions congratulates Professor John Hardy of the Institute of Neurology at UCL on winning the Breakthrough Prize for his pioneering research into the genetic causes of Alzheimer’s disease, dementia and Parkinsons disease.You can read the full article by clicking on the following link
Press release - Feinstein Institute researcher, Prof Peter Davies, awarded 2015 Potamkin Prize
mar 25, 2015 | CBD Solutions congratulates Professor Peter Davies of the Feinstein Institute for Medical Research in New York, who together with Reisa A. Sterling, M.D of Massachusetts General Hospital in Boston, were awarded the 2015 Potamkin Prize The prize honours researchers for their work in helping to advance the understanding of Pick’s disease, Alzheimer’s disease and related disorders.
CBD Solutions 2nd Scientific Investigators Meeting, 27 February 2015, London
mar 1, 2015 | CBD Solutions recently brought together leading scientists in this very special field of medical research at its 2nd Scientific Investigators Meeting. This meeting was held on the 27th February at the impressive Dorchester Library at the Royal College of Physicians in London and was attended by researchers from Germany, Japan, Sweden, the UK and the USA.
CBD Solutions supports UCSF Study
apr 1, 2014 | CBD Solutions is a non-profit organisation supporting research in corticobasal degeneragtion. CBD Solutions will financially support the University of California San Francisco (UCSF) Foundation to allow Dr Adam Boxer to conduct a study understanding whether the stabilization of microtubules, through use of a stabilizing drug known as TPI287, might be a safe and effective treatment for CBD. CBD Solutions official policy on research grant funding is to allow no more than 5% indirect expenses to be assessed by a sponsoring institution on any CBD Solutions funded projects.
dec 6, 2013 | CurePSP and CBD Solutions partner to create CBD Rating Scale. Click here to read press release.
nov 21, 2013 | NsGene and partners receive grant to investigate novel therapy for Cortico-Basal Degeneration (CBD) Click here to read press release.
sep 27, 2013 | Unique research effort on rare disease. Relatively little research is being conducted into the neurological disease CBD, and as a result of which, not much is known about the as yet incurable and terminal disease...
Karolinska Institutet Seminars
sep 2, 2013 | Corticobasal degenerationon - From molecular mechanisms to potential treatment. Click here to read more